Interesting company, not long ago got a $750,000 grant from the Vic government. Its main work seems to be towards ovarian cancer. Is anyone else on this one? Very thinly traded but got some at .08 and .085.
From the web site;
Welcome to HealthLinx Limited HealthLinx is an emerging biomarker and diagnostic company with an integrated platform in biomarker and bioactive peptide discovery platforms. Our core focus is on the development of novel blood based diagnostics for targeted diseases that have un-met market need.
Clinical practice and public health are moving from generic, episodic treatment approaches towards personalised and preventive medicine. The trend in the pharmaceutical industry is towards developing better and earlier diagnostics and disease-targeted therapies. Food companies are also directing focus to functional foods as a means of improving community health. These market trends converge and are aligned with HealthLinx’s vision and mission.
HealthLinx will berecognisedas a leader in delivering diagnostic applications to improve health outcomes.
HealthLinx develops novel, non-invasive, serum-based, diagnostic products. The Ovarian Cancer Program has completed a phase II biomarker trial with the outcome being the development of the first generation ovarian cancer diagnostic, OvPlex™.
OvPlex™ is a panel of six markers including the gold standard CA125. The trial screened 150 diseased samples and 212 normal samples. Statistical significance was achieved for the detection of early stage ovarian cancer as interpreted by an independent biostatistician.
The company released OvPlex™ in the Australian market in October 2008 through its distribution partner, ARL Pathology (now Healthscope), as an elective test.
HTX Price at posting:
9.3¢ Sentiment: Buy Disclosure: Held
